Epimacular Brachytherapy Reduces Re-Treatment For Up To 2 Years

Wednesday, July 2, 2014

Comments

Ocular Surgery News

Epimacular brachytherapy safely reduced ranibizumab re-treatments for up to 1 year in patients with neovascular age-related macular degeneration, according to a study.

Full Abstract

The patient in the photos below is a 45 yo female with complaints of a bulging right eye that has been gradual over the past several years. She denies pain or double vision. Her CT scans are shown below as well as the surgical removal of the tumor. What is the most likely diagnosis?
1. schwannoma
2. cavernous hemangioma
3. capillary hemangioma
4. metastatic breast cancer
Check The Answer

OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product
Selecta Trio™ YAG Laser, SLT and Photocoagulation
The Lumenis Selecta® Trio™ ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Epimacular Brachytherapy Reduces Re-Treatment For Up To 2 Years

Comments

Quick Quiz

The patient in the photos below is a 45 yo female with complaints of a bulging right eye that has been gradual over the past several years. She denies pain or double vision. Her CT scans are shown below as well as the surgical removal of the tumor. What is the most likely diagnosis?

AdGlare RMR Ad

Featured Products

OPMI LUMERA 700 Surgical Microscope

Selecta Trio™ YAG Laser, SLT and Photocoagulation

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us